{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:47:30Z","timestamp":1791463650604,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108182","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:58:14Z","timestamp":1737374294000},"page":"108182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["New molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers"],"prefix":"10.1016","volume":"156","author":[{"given":"Magda M.F.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghreed Z.","family":"Shawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousry A.","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108182_b0005","doi-asserted-by":"crossref","unstructured":"Maharani, R., Muhajir, M. I., Dirgantara, J. M., Hardianto, A., Mayanti, T., Harneti, D., Nurlelasari, Farabi, K., Hidayat, A. T., Supratman, U., & Siahaan, T. (2024), Synthesis and anticancer evaluation of [d-Ala]-nocardiotide A. RSC Adv., 14(6), 4097\u20134104. https:\/\/doi.org\/10.1039\/d4ra00025k.","DOI":"10.1039\/D4RA00025K"},{"key":"10.1016\/j.bioorg.2025.108182_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discovery"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108182_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107157","article-title":"Design, synthesis, and anticancer evaluation of N-Sulfonyl-piperidines as potential VEGFR-2 inhibitors, apoptotic inducers","volume":"145","author":"Elgammal","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108182_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105291","article-title":"Hypoxic regulation of hypoxia inducible factor 1 alpha via antisense transcription","volume":"299","author":"Downes","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0030","doi-asserted-by":"crossref","unstructured":"Liu Y. ,Li ,Yuxi Wang,Congcong Lin,Zhang D.,Chen J. ,Ouyang L., WuF. ,Zhang J., ChenL. (2022), Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy, Journal of Hematology and Oncology, 7, 15-89. doi:10.1186\/s13045-022-01310-7.","DOI":"10.1186\/s13045-022-01310-7"},{"key":"10.1016\/j.bioorg.2025.108182_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0040","doi-asserted-by":"crossref","unstructured":"Feng, L. S., Gao, C., Liu, F. W., Wang, X. P., & Zhang, Z. L. (2022), Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022), Current topics in medicinal chemistry, 22(17), 1426\u20131441. https:\/\/doi.org\/10.2174\/1568026622666220428093955.","DOI":"10.2174\/1568026622666220428093955"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108182_b0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/molecules24061175","article-title":"Design and Synthesis of New Quinoxaline Derivatives as Anticancer Agents and Apoptotic Inducers","volume":"24","author":"El Newahie","year":"2019","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108182_b0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2478\/acph-2019-0013","article-title":"Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents","volume":"69","author":"Ajani","year":"2019","journal-title":"Acta Pharm. (Zagreb, Croatia)"},{"key":"10.1016\/j.bioorg.2025.108182_b0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bioorg.2018.03.002","article-title":"Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors","volume":"78","author":"Akhtar","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108182_b0060","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/molecules23081956","article-title":"Synthesis of new 1, 3, 5-triazine-based 2-pyrazolines as potential anticancer agents","volume":"23","author":"Moreno","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108182_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115495","article-title":"Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers","volume":"257","author":"Xu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135765","article-title":"Design, synthesis, molecular docking and biological evaluation of novel pyrazole derivatives bearing quinoxalinone moiety as multi-targeted anticancer agents","volume":"1288","author":"Theodore","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108182_b0075","doi-asserted-by":"crossref","unstructured":"Hasanzad, M., Sarhangi, N., Meybodi, H. R. A., & Nikfar, S. (2023). Pharmacogenetics and toxicology. Encyclopedia of Toxicology (4 ed., Vol 7, Pages 467-491. https:\/\/doi.org\/10.1016\/B978-0-12-824315-2.01077-0.","DOI":"10.1016\/B978-0-12-824315-2.01077-0"},{"issue":"13","key":"10.1016\/j.bioorg.2025.108182_b0080","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/cancers13133206","article-title":"Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin","volume":"13","author":"Deininger","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10428194.2017.1324155","article-title":"Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2025.108182_b0090","doi-asserted-by":"crossref","DOI":"10.21037\/gist-21-6","article-title":"New molecularly targeted drugs for gist after imatinib, sunitinib and regorafenib: A narrative review","volume":"5","author":"Mazzocca","year":"2022","journal-title":"Gastrointestinal Stromal Tumor"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.18576\/jpac\/030109","article-title":"Design, synthesis and QSAR studies of novel 1, 3, 4-triarylpyrazoles as anti-breast cancer agents","volume":"3","author":"Farrag","year":"2017","journal-title":"J. Pharm. Appl. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000214","article-title":"Synthesis of new arylazopyrazoles as apoptosis inducers: Candidates to inhibit proliferation of MCF-7 cells","volume":"354","author":"Ismail","year":"2021","journal-title":"Arch. Pharm."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108182_b0105","first-page":"948","article-title":"Novel 1, 3, 4-triaryl pyrazoles: synthesis, QSAR studies and cytotoxicity against breast cancer","volume":"19","author":"Ismail","year":"2019","journal-title":"Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"key":"10.1016\/j.bioorg.2025.108182_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104368","article-title":"Design and synthesis of novel tranilast analogs: Docking, antiproliferative evaluation and in-silico screening of TGF\u03b2R1 inhibitors","volume":"105","author":"Ismail","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104378","article-title":"New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study","volume":"105","author":"Farrag","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103481","article-title":"Apoptosis: A target for anticancer therapy with novel cyanopyridines","volume":"94","author":"Ismail","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108182_b0125","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1002\/jhet.4064","article-title":"Synthesis, anticancer screening, and in silico ADME prediction of novel 2-pyridones as Pim inhibitors","volume":"57","author":"Ismail","year":"2020","journal-title":"J. Heterocycl. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108182_b0130","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bioorg.2017.12.003","article-title":"Synthesis, anti-inflammatory, p38\u03b1 MAP kinase inhibitory activities and molecular docking studies of quinoxaline derivatives containing triazole moiety","volume":"76","author":"Tariq","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"45","key":"10.1016\/j.bioorg.2025.108182_b0140","doi-asserted-by":"crossref","first-page":"31908","DOI":"10.1039\/D3RA05066A","article-title":"Novel quinoxaline-3-propanamides as VGFR-2 inhibitors and apoptosis inducers","volume":"13","author":"Ismail","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108182_b0145","first-page":"151","article-title":"3-Ethoxycarbonylmethylenequinoxalin-2-one in Heterocyclic Synthesis, Part 1: Synthesis of New Substituted and Condensed Quinoxalines","volume":"516","author":"Ammar","year":"2005","journal-title":"AFINIDAD-BARCELONA-"},{"key":"10.1016\/j.bioorg.2025.108182_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130317","article-title":"Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors","volume":"1236","author":"Fayed","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108182_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106735","article-title":"Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis","volume":"139","author":"Ismail","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12039-021-01902-9","article-title":"Preparative, mechanistic and tautomeric investigation of 1-phenyl and 1-methyl derivative of 3-methyl-5-pyrazolone","volume":"133","author":"Fakhraian","year":"2021","journal-title":"J. Chem. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108182_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01376","article-title":"Chalcone derivatives: synthesis,invitroandinvivoevaluation of their anti-anxiety, anti-depression and analgesic effects","volume":"5","author":"Higgs","year":"2019","journal-title":"Heliyon"},{"issue":"32","key":"10.1016\/j.bioorg.2025.108182_b0170","doi-asserted-by":"crossref","first-page":"27769","DOI":"10.1021\/acsomega.2c01779","article-title":"Synthesis of Chalcones Derivatives and Their Biological Activities: A Review","volume":"7","author":"Elkanzi","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108182_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.materresbull.2013.11.003","article-title":"Synthesis, crystal growth, studies on vibrational spectroscopy and nonlinear optical properties of 4-methoxy-4\u2032-chlorochalcone","volume":"50","author":"Prabu","year":"2014","journal-title":"Mater. Res. Bull."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108182_b0180","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1016\/j.bmc.2006.06.038","article-title":"New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides","volume":"14","author":"Amin","year":"2006","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.20884\/1.jm.2020.15.1.585","article-title":"Synthesis, Antiproliferative Activity and Molecular Docking Studies of 1,3,5-Triaryl Pyrazole Compound as Estrogen \u03b1 Receptor Inhibitor Targeting MCF-7 Cells Line","volume":"15","author":"Herfindo","year":"2020","journal-title":"Molekul"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108182_b0190","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1128\/AEM.65.8.3727-3729.1999","article-title":"The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities","volume":"65","author":"Freimoser","year":"1999","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.bioorg.2025.108182_b0195","unstructured":"VEGFR-2 (KDR) kinase assay kit catalog, 40325, info@bpsbioscience.com, www.bpsbioscience.com."},{"key":"10.1016\/j.bioorg.2025.108182_b0200","unstructured":"PDGFR\u03b1 (D842I) Assay Kit, Catalog 79761, info@bpsbioscience.com, www.bpsbioscience.com."},{"key":"10.1016\/j.bioorg.2025.108182_b0205","unstructured":"EGFR kinase Assay kit, Catalog 40321, info@bpsbioscience.com, www.bpsbioscience.com."},{"key":"10.1016\/j.bioorg.2025.108182_b0210","series-title":"Molecular cloning: a laboratory manual","author":"Sambrook","year":"1989"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108182_b0215","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1038\/emm.2017.248","article-title":"Rab25 augments cancer cell invasiveness through a \u03b21 integrin\/EGFR\/VEGF-A\/Snail signaling axis and expression of fascin","volume":"50","author":"Jeong","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108182_b0220","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/healthcare9070911","article-title":"Modeling and Predicting the Cell Migration Properties from Scratch Wound Healing Assay on Cisplatin-Resistant Ovarian Cancer Cell Lines Using Artificial Neural Network","volume":"9","author":"Bahar","year":"2021","journal-title":"Healthcare"},{"key":"10.1016\/j.bioorg.2025.108182_b0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-8-8","article-title":"Centrosome-associated regulators of the G(2)\/M checkpoint as targets for cancer therapy","volume":"8","author":"Wang","year":"2009","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108182_b0230","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108182_b0235","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1016\/j.bmc.2009.06.069","article-title":"Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach","volume":"17","author":"Lakshmi","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108182_b0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001883","article-title":"Tumor suppressive functions of p53","volume":"1","author":"Zilfou","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108182_b0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd3137","article-title":"Targeting mitochondria for cancer therapy","volume":"9","author":"Fulda","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108182_b0250","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2025.108182_b0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108182_b0260","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108182_b0265","doi-asserted-by":"crossref","unstructured":"Da Silva, M. M., Comin, M., Duarte, T. S., Foglio, M. A., de Carvalho, J. E., do Vieira, M. C., & Formagio, A. S. (2015), Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives, Molecules (Basel, Switzerland), 20(4), 5360\u20135373. https:\/\/doi.org\/10.3390\/molecules20045360.","DOI":"10.3390\/molecules20045360"},{"issue":"30","key":"10.1016\/j.bioorg.2025.108182_b0270","doi-asserted-by":"crossref","first-page":"20443","DOI":"10.1039\/D3RA02579A","article-title":"Design, synthesis, and docking studies of novel pyrazole-based scaffolds and their evaluation as VEGFR2 inhibitors in the treatment of prostate cancer","volume":"13","author":"Soliman","year":"2023","journal-title":"RSC Adv."},{"issue":"4\u20136","key":"10.1016\/j.bioorg.2025.108182_b0275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cplett.2008.03.028","article-title":"Interplay between cation-\u03c0 and hydrogen bonding interactions","volume":"456","author":"Escudero","year":"2008","journal-title":"Chem. Phys. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T01:56:30Z","timestamp":1758851790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":55,"alternative-id":["S0045206825000628"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108182","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108182"}}